DYAX Share Price

Open 38.36 Change Price %
High 38.56 1 Day 0.10 0.26
Low 38.25 1 Week 0.00 0.00
Close 38.41 1 Month 0.00 0.00
Volume 12524978 1 Year 0.00 0.00
52 Week High 5.56
52 Week Low 3.00
DYAX Important Levels
Resistance 2 38.70
Resistance 1 38.58
Pivot 38.41
Support 1 38.24
Support 2 38.12
NASDAQ USA Most Active Stocks
ASTI 0.01 0.00%
QCOM 54.88 -12.72%
QCOM 54.88 -12.72%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
More..
NASDAQ USA Top Gainers Stocks
EDMC 0.02 100.00%
CPSL 0.10 66.67%
LOCM 0.09 50.00%
ACFN 0.30 30.43%
LTRE 2.85 29.55%
WRES 0.09 28.57%
QKLS 0.14 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Dyax Corp. (NASDAQ: DYAX)

DYAX Technical Analysis 5
As on 21st Jan 2016 DYAX Share Price closed @ 38.41 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 26.49 & Strong Buy for SHORT-TERM with Stoploss of 36.25 we also expect STOCK to react on Following IMPORTANT LEVELS.
DYAX Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
DYAX Other Details
Segment EQ
Market Capital 315442656.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.dyax.com
DYAX Address
DYAX
55 Network Drive
Burlington, MA 01803
United States
Phone: 617-225-2500
Fax: 617-225-2501
DYAX Latest News
Interactive Technical Analysis Chart Dyax Corp. ( DYAX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Dyax Corp.
DYAX Business Profile
Dyax Corp. (Dyax), is a biopharmaceutical company with two business elements: Angioedema Franchise and Phage Display Licensing and Funded Research Program. It is focused on identifying and developing treatments for patients who experience plasma kallikrein (bradykinin) mediated angioedema. The principal focus of Dyax is to identify, develop and commercialize treatments for conditions identified as plasma kallikrein (bradykinin) mediated angioedema, including hereditary angioedema (HAE), ACE inhibitor-induced angioedema (ACEI-AE) and angioedema of unknown origin, or idiopathic angioedema. It developed KALBITOR (ecallantide) on its own in the United States for the treatment of acute attacks of HAE. Outside of the United States, it has established partnerships to obtain regulatory approval for and commercialize KALBITOR in certain markets and it is evaluating opportunities in others. It leverages its phage display technology through the Licensing and Funded Research Program (LFRP).